Aravive, Inc.

NasdaqGS:ARAV 株式レポート

時価総額:US$2.9m

Aravive バランスシートの健全性

財務の健全性 基準チェック /36

Aravive has a total shareholder equity of $1.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $13.0M and $11.3M respectively.

主要情報

0%

負債資本比率

US$0

負債

インタレスト・カバレッジ・レシオn/a
現金US$8.54m
エクイティUS$1.70m
負債合計US$11.35m
総資産US$13.05m

財務の健全性に関する最新情報

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Apr 26
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Aravive Q2 GAAP EPS misses, revenue beats

Aug 11

Aravive appoints Robert Geller as CMO

Jul 05

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive EPS beats by $0.01, misses on revenue

May 06

Aravive shares rise after dosing first patient in late-stage ovarian cancer study

Apr 27

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Aravive: Pipeline-In-A-Pill In Oncology

Dec 28

Aravive (ARAV) Investor Presentation - Slideshow

Dec 04

Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative

Nov 19

Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China

Nov 10

財務状況分析

短期負債: ARAV's short term assets ($9.6M) do not cover its short term liabilities ($9.8M).

長期負債: ARAV's short term assets ($9.6M) exceed its long term liabilities ($1.6M).


デット・ツー・エクイティの歴史と分析

負債レベル: ARAV is debt free.

負債の削減: ARAV has not had any debt for past 5 years.


貸借対照表


キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: ARAV has less than a year of cash runway based on its current free cash flow.

キャッシュランウェイの予測: ARAV has less than a year of cash runway if free cash flow continues to grow at historical rates of 8% each year.


健全な企業の発掘